{
  "generated_at": "2026-01-25",
  "methodology": "External validation via ClinicalTrials.gov and PubMed",
  "prioritized_candidates": {
    "tier_1_high_priority": {
      "description": "Strong model signal + moderate external evidence = potential novel repurposing",
      "candidates": [
        {
          "drug": "Sirolimus",
          "disease": "Psoriasis",
          "model_score": "High",
          "validation_score": 0.40,
          "rationale": "mTOR inhibitor. mTOR pathway implicated in psoriasis pathogenesis. Could be alternative to biologics.",
          "next_steps": ["Literature deep dive on mTOR in psoriasis", "Check for ongoing trials"]
        },
        {
          "drug": "Clopidogrel",
          "disease": "Rheumatoid Arthritis",
          "model_score": "High",
          "validation_score": 0.37,
          "rationale": "Antiplatelet agent. Emerging evidence for platelet-immune system crosstalk in RA.",
          "next_steps": ["Review platelet-inflammation research", "Assess safety profile for chronic use"]
        },
        {
          "drug": "Everolimus",
          "disease": "Rheumatoid Arthritis",
          "model_score": "High",
          "validation_score": 0.30,
          "rationale": "mTOR inhibitor already used in transplant. Shares mechanism with sirolimus.",
          "next_steps": ["Compare to sirolimus RA data", "Check for synergy with existing DMARDs"]
        },
        {
          "drug": "Metformin",
          "disease": "Breast Cancer",
          "model_score": "High",
          "validation_score": 0.21,
          "rationale": "Well-known repurposing candidate. Multiple epidemiological studies show reduced cancer risk in diabetics on metformin.",
          "next_steps": ["This is already being actively investigated - review trial status"]
        },
        {
          "drug": "Digoxin",
          "disease": "Type 2 Diabetes",
          "model_score": 1.05,
          "validation_score": 0.88,
          "rationale": "Cardiac glycoside with 8 trials and 45 publications. Unexpected metabolic connection.",
          "next_steps": ["Deep dive on digoxin-glucose metabolism link", "Check for Na/K-ATPase metabolic effects"]
        }
      ]
    },
    "tier_2_emerging": {
      "description": "Novel predictions with some literature support",
      "candidates": [
        {
          "drug": "Panitumumab",
          "disease": "Gastric Adenocarcinoma",
          "validation_score": 0.45,
          "rationale": "Anti-EGFR mAb. EGFR overexpressed in gastric cancer. Extension of CRC indication."
        },
        {
          "drug": "Olaparib",
          "disease": "Breast Cancer",
          "validation_score": 0.34,
          "rationale": "PARP inhibitor. Already approved for BRCA+ breast cancer - model capturing this."
        },
        {
          "drug": "Busulfan",
          "disease": "Plasma Cell Myeloma",
          "validation_score": 0.36,
          "rationale": "Alkylating agent used in conditioning. Some use in myeloma protocols."
        }
      ]
    },
    "tier_3_novel_unvalidated": {
      "description": "High model scores with minimal external evidence - truly novel or spurious",
      "candidates": [
        {
          "drug": "Paclitaxel",
          "disease": "Rheumatoid Arthritis",
          "model_score": 1.09,
          "validation_score": 0.0,
          "note": "Top model prediction but no trials/pubs. Mechanism unclear - needs investigation."
        },
        {
          "drug": "Teniposide",
          "disease": "Rheumatoid Arthritis",
          "model_score": 1.07,
          "validation_score": 0.0,
          "note": "Topoisomerase II inhibitor. Why RA? Possible anti-proliferative effect on synoviocytes?"
        }
      ]
    }
  },
  "validation_statistics": {
    "total_validated": 100,
    "with_trials": 61,
    "with_publications": 89,
    "strong_evidence": 57,
    "moderate_evidence": 10,
    "weak_evidence": 23,
    "no_evidence": 10
  },
  "key_findings": [
    "57% of top predictions have strong external evidence - model is learning real patterns",
    "10% have moderate evidence - best repurposing candidates for follow-up",
    "Model correctly identifies approved indications (Cetuximab/CRC, Bevacizumab/CRC, etc.)",
    "mTOR inhibitors (Sirolimus, Everolimus) show consistent signal for autoimmune diseases",
    "Digoxin for T2D is unexpected but has 8 trials - warrants investigation"
  ]
}
